Compass Pathways PLC Sponsored ADR $CMPS Shares Newly Purchased by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC bought a new position in shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund bought 198,400 shares of the company’s stock, valued at approximately $2,468,000. Lisanti Capital Growth LLC owned 0.14% of Compass Pathways at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of CMPS. EverSource Wealth Advisors LLC increased its holdings in Compass Pathways by 67.7% during the first quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock worth $26,000 after buying an additional 1,920 shares during the last quarter. Parallel Advisors LLC lifted its stake in Compass Pathways by 8,450.6% in the first quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock valued at $40,000 after acquiring an additional 7,183 shares during the last quarter. Ancora Advisors LLC bought a new position in shares of Compass Pathways in the 2nd quarter valued at about $43,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Compass Pathways in the 3rd quarter valued at about $85,000. Finally, Entropy Technologies LP acquired a new position in shares of Compass Pathways during the 1st quarter worth about $110,000. 46.19% of the stock is owned by institutional investors.

Compass Pathways Stock Up 0.5%

Compass Pathways stock opened at $9.30 on Thursday. The stock has a market cap of $1.32 billion, a P/E ratio of -2.66 and a beta of 2.43. The company has a quick ratio of 1.50, a current ratio of 1.50 and a debt-to-equity ratio of 0.35. Compass Pathways PLC Sponsored ADR has a twelve month low of $4.88 and a twelve month high of $15.87. The company’s 50-day moving average price is $12.06 and its two-hundred day moving average price is $10.44.

Compass Pathways (NASDAQ:CMPS) last issued its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.08. As a group, analysts expect that Compass Pathways PLC Sponsored ADR will post -0.78 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Wells Fargo & Company dropped their target price on shares of Compass Pathways from $13.00 to $10.00 and set an “equal weight” rating on the stock in a report on Wednesday, November 4th. Morgan Stanley raised their price objective on Compass Pathways from $17.00 to $18.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. HC Wainwright reaffirmed a “buy” rating on shares of Compass Pathways in a report on Monday. B. Riley Financial lifted their price objective on shares of Compass Pathways from $17.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Finally, Royal Bank Of Canada reiterated an “outperform” rating on shares of Compass Pathways in a report on Wednesday, November 4th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Compass Pathways currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.14.

Latest Compass Pathways News

Investors following CMPS have been watching these news items:

• Positive Sentiment: HC Wainwright’s updated estimates project narrower losses: its FY2026 EPS forecast improved to ($1.40) from ($1.58), and its FY2027 forecast to ($1.17) from ($1.56). The firm also raised estimates across the reported quarters through 2027 and maintained its Buy rating. Better-than-previous forecasts may support investor sentiment, though the company is still expected to post losses. Compass Pathways analyst estimates
• Neutral Sentiment: Compass Pathways plans to attend the Jefferies Global Healthcare Conference on November 18–19, including a fireside chat and panel. The appearance could provide investor visibility, but the announcement did not disclose new company developments. Conference announcement

Compass Pathways Company Profile

Compass Pathways plc is a biotechnology company developing treatments for mental health conditions. Founded in 2016 by George Goldsmith and Ekaterina Malievskaia, the company is focused on advancing psychedelic-based therapies through clinical research. Its lead investigational product, COMP360, is a synthetic formulation of psilocybin being studied alongside psychological support. Compass is evaluating COMP360 primarily as a potential treatment for treatment-resistant depression and has also explored its use for other mental health conditions, including post-traumatic stress disorder.